It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

2017

Evotec Receives Clinical Milestone as Part of its Discovery Alliance with Boehringer Ingelheim
Nerina Coppini, 1 December 2017

ACHIEVEMENT MARKS 24TH MILESTONE UNDER ALLIANCE TO DATE Hamburg, Germany, 01 December 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that it has achieved a clinical milestone under its drug discovery alliance with Boehringer Ingelheim triggering revenues of € 2.00 m to Evotec. The milestone was for...

Aptuit Selected as a Winner of Life Science Leader Global Award for Contract Drug Manufacturer in Multiple Categories
Nerina Coppini, 13 March 2017

Greenwich, CT – March 13, 2017 - Aptuit, LLC today announced that the company has been selected as a winner of four Contract Manufacturer Organization (CMO) Leadership Awards by Life Science Leader magazine. Aptuit was selected from a survey of pharma and biopharma companies who had outsourced projects within the past 18 months. Customers judge...

SAMDI Tech, Inc. and Aptuit Announce Drug Discovery Screening Partnership
Nerina Coppini, 7 February 2017

CHICAGO, IL – February 7, 2017 – SAMDI Tech, Inc. and Aptuit, LLC are partnering to broaden their portfolio of assay development and high-throughput drug discovery services in Europe and North America. The partnership provides early-stage drug discovery researchers with access to SAMDI Tech’s unique label-free platform as well as Aptuit’s broad...

Chronos Therapeutics partners with Aptuit for addictive behaviour programmes
Nerina Coppini, 10 January 2017

Oxford, UK - January 9, 2017 - Chronos Therapeutics Ltd (Chronos), the private biotech company focused on ageing diseases, brain and nervous system disorders, announced that they have partnered with a subsidiary of Aptuit Holdings LLC (Aptuit) for services related to Chronos’ programme targeting the addictive behaviours of binge eating and...

Aptuit and Chiesi Initiate Integrated Discovery Project to Identify Novel Compounds for the Treatment of Idiopathic Pulmonary Fibrosis
Nerina Coppini, 4 January 2017

Greenwich, CT, and Parma, Italy – January 4, 2017 Aptuit, LLC, a premier global drug discovery and development CRO, and Chiesi Farmaceutici (Chiesi), an international research-focused Healthcare Group, announced today that they have entered an agreement under which Aptuit will conduct an integrated Discovery Project aimed at providing...

2016

Aptuit Announces Expansion of Compound Library
Nerina Coppini, 30 November 2016

Part of 5m$ Investment in Integrated Drug Discovery Capabilities Greenwich, CT, November 30, 2016 - Aptuit, LLC today announced that it had successfully completed the expansion of their lead-like screening library. An additional 150,000 novel compounds have increased the Screening Collection to over 400,000. The new compounds were carefully...

Aptuit announces enhancement of integrated IND enabling services
Nerina Coppini, 13 October 2016

Expanding capabilities and capacity in formulation development and safety assessment Greenwich, CT, October 13, 2016 - Aptuit, LLC today announced that it has relocated its recently acquired subsidiary Kuecept to its Oxford UK site, and added further formulation and safety assessment capacity to meet sustained customer demand for IND de-risking...

Aptuit LLC and Dimension Therapeutics enter strategic partnership to advance select Dimension programs toward IND filing
Nerina Coppini, 7 July 2016

Aptuit Greenwich, CT, and Cambridge, MA - July 7, 2016 – Aptuit LLC, a premier global drug discovery and development CRO, and Dimension Therapeutics, a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, announced today a strategic partnership...

Aptuit announces acquisition of Kuecept Ltd
Jim Regan, 10 May 2016

Expanding capabilities in formulation development to include specialist pre-formulation, formulation prototyping and formulation development services Greenwich, CT, May, 10th, 2016 - Aptuit, LLC today announced that it has acquired Kuecept Ltd to meet strong customer demand for specialist drug pre-formulation, formulation prototyping and...

Aptuit announces acquisition of Exquiron Biotech AG
Jim Regan, 21 April 2016

Expands Capabilities in Discovery to Include High Throughput Screening and Other Early Discovery Services Greenwich, CT, April 21st, 2016 - Aptuit, LLC today announced that it has acquired Exquiron Biotech AG to meet customer demand for fully integrated outsourced discovery services. Exquiron is a leading specialist Contract Research...

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard